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Abstract
OBJECTIVE—We aimed to determine the frequency of qacA/B chlorhexidine tolerance genes 
and high-level mupirocin resistance among MRSA isolates before and after the introduction of a 
chlorhexidine (CHG) daily bathing intervention in a surgical intensive care unit (SICU).
DESIGN—Retrospective cohort study (2005–2012)
SETTING—A large tertiary-care center
PATIENTS—Patients admitted to SICU who had MRSA surveillance cultures of the anterior 
nares
METHODS—A random sample of banked MRSA anterior nares isolates recovered during (2005) 
and after (2006–2012) implementation of a daily CHG bathing protocol was examined for qacA/B 
genes and high-level mupirocin resistance. Staphylococcal cassette chromosome mec (SCCmec) 
typing was also performed.
RESULTS—Of the 504 randomly selected isolates (63 per year), 36 (7.1%) were qacA/B positive 
( + ) and 35 (6.9%) were mupirocin resistant. Of these, 184 (36.5%) isolates were SCCmec type 
IV. There was a significant trend for increasing qacA/B (P= .02; highest prevalence, 16.9% in 2009 
and 2010) and SCCmec type IV (P< .001; highest prevalence, 52.4% in 2012) during the study 
period. qacA/B( + ) MRSA isolates were more likely to be mupirocin resistant (9 of 36 [25%] 
qacA/B( + ) vs 26 of 468 [5.6%] qacA/B(−); P= .003).
CONCLUSIONS—A long-term, daily CHG bathing protocol was associated with a change in the 
frequency of qacA/B genes in MRSA isolates recovered from the anterior nares over an 8-year 
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period. This change in the frequency of qacA/B genes is most likely due to patients in those years 
being exposed in prior admissions. Future studies need to further evaluate the implications of 
universal CHG daily bathing on MRSA qacA/B genes among hospitalized patients.
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare-
associated infections.1–3 Compared with methicillin-susceptible strains, MRSA is associated 
with increased risk of adverse health outcomes and increased treatment costs.4,5 Multiple 
studies have shown that MRSA nasal colonization is a risk factor for subsequent MRSA 
infection.6–8 Interventions to interrupt MRSA transmission among hospitalized patients 
include active surveillance for colonization and contact precautions.9,10
Recently, the use of chlorhexidine (CHG)-based body wash, either alone or in combination 
with intranasal antibiotics such as mupirocin, has been demonstrated to reduce the incidence 
of MRSA transmission and subsequent infection among hospitalized patients.11–13 However, 
widespread use of chlorhexidine may result in the selection of bacteria that are chlorhexidine 
tolerant, with the potential to limit the effectiveness of this intervention in the future. In S. 
aureus, chlorhexidine tolerance is associated with the qac gene family (qacA/B), which code 
for efflux pumps capable of extruding chlorhexidine and other biocidal compounds from the 
cell.14–17 The presence of qacA/B has been associated with elevated minimum bactericidal 
concentrations for chlorhexidine and MRSA decolonization protocol failures.18,19 The 
implementation of a daily topical chlorhexidine antiseptic protocol among ICU patients 
resulted in the selection of a qacA/B–positive ( + ) MRSA strain, while the transmission of 
other MRSA strains was reduced during the 2-year period.20 Some plasmids harboring the 
qac genes may contain additional antibiotic resistance genes.14,17,21 In vitro evidence that 
CHG may induce selective pressure in clinical MRSA isolates18,20 highlights the importance 
of antiseptic tolerance evaluation as part of infection control practices.
Mupirocin, a topical antibiotic, is widely used for treatment of uncomplicated skin and soft-
tissue infections and MRSA decolonization. Resistance to mupirocin is broadly classified as 
low-level resistance (typically defined as having a minimum inhibitory concentration [MIC] 
of 8–256 mg/L), and high-level resistance (MIC ≥ 512 mg/L)18,20,22,23 is most commonly 
conferred by the plasmid-borne mupA gene, although other mechanisms have been 
reported.24–26 Mupirocin resistance has been associated with reduced effectiveness of 
decolonization strategies.27 Its prevalence is variable, ranging from 4% among MRSA 
isolates in Canadian hospitals to as much as 80% in a Swiss hospital in the context of 
widespread mupirocin use.28,29
Based upon studies of chlorhexidine-based daily bathing protocols and subsequent MRSA 
infection, this practice is becoming more widespread in hospitals. However, the longterm 
effects of daily chlorhexidine bathing on the prevalence of qacA/B resistance genes in 
MRSA isolates in the hospital setting is unknown.
The objective of this study was to determine changes in the frequency of qacA/B gene 
carriage and mupA-mediated high-level mupirocin resistance among nasal MRSA isolates 
recovered from active surveillance nasal cultures in the 8-year period during and following 
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implementation of a universal chlorhexidine bathing intervention in a surgical intensive care 
unit (SICU).
METHODS
Study Design and Setting
We conducted a retrospective cohort study of patients admitted between 2005 and 2012 to 
the 24-bed surgical intensive care unit of Barnes-Jewish Hospital (BJC), a 1,250-bed 
tertiary-care hospital in St. Louis, Missouri.
Chlorhexidine Bathing Intervention
On June 1, 2005, the SICU implemented a daily chlorhexidine bathing protocol, replacing a 
once-daily bath with non-medicated soap and water. Daily water basin baths used 4% 
chlorhexidine gluconate soap (Exidine, Cardinal Health, McGraw Park, IL). Compliance, as 
measured by number of soap bottles used per patient day, was >90%. Chlorhexidine soap 
was diluted in water to achieve a final concentration of approximately 0.125% (1,250 µg/
mL). There was no routine use of intranasal mupirocin during this time period.
Data Collection
All patients admitted to the SICU had a swab of the anterior nares obtained for MRSA 
surveillance cultures per the hospital infection prevention policy. Patients who stayed for >2 
days had nasal swabs weekly and at SICU discharge. All MRSA isolates were saved from 
2005 to 2012. For this study, isolates from patients admitted to the SICU in 2005 were 
considered to be collected in the implementation period, and the post-implementation period 
was 2006–2012.
We estimated a MRSA qacA/B baseline prevalence of 1%, based upon a study of household 
prevalence in the Saint Louis community.30 Thus, we estimated that 63 randomly selected 
isolates per year (504 total) would be required to detect a 1% per year increase in prevalence 
of qacA/B positivity during the study period (β = 0.80 and α = 0.05). Random sampling was 
done by computer analysis using SPSS version 20 (IBM SPSS, Chicago, IL).
Patient demographics, length of stay in days (LOS, median [interquartile range, IQR]), 
previous hospitalization history, presence of comorbidities and other characteristics were 
obtained from the Barnes-Jewish Hospital (BJC) medical informatics database for all 
patients whose isolates were included in this study. Patients with negative admission cultures 
but subsequently had a positive nasal MRSA culture during the SICU admission were 
considered to have ICU-acquired MRSA.
Microbiological Methods
MRSA culture testing was performed as described previously.31 Isolates were stored in skim 
milk at −70°C prior to analysis. Selected isolates were subcultured on sheep’s blood agar. 
MRSA was confirmed using cefoxitin disk diffusion testing according to CLSI standards.32 
Selected samples underwent amplification14 of the qacA/B genes using a polymerase chain 
reaction (PCR) with the following primers: F: 5’-CTA TGG CAA TAG GAG ATA TGG 
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TGT -3’, R: 5’- CCA CTA CAG ATT CTT CAG CTA CAT G -3’. As a confirmatory test, a 
second set of qacA/B PCR was performed on all initially positive isolates.30
We performed mupirocin phenotypic susceptibility testing by Kirby-Bauer disk diffusion 
using a 200-µg mupirocin disk (Oxoid, Hampshire, UK) on Mueller-Hinton agar (Hardy 
Diagnostics, Santa Maria, CA).23 Isolates with no zone of inhibition around the mupirocin 
disk were classified as mupirocin resistant. All mupirocin-resistant isolates underwent PCR 
amplification for detection of mupA30,32,33 using the following primers: F: 5’-TAT ATT 
ATG CGA TGG AAG GTT GG -3’, R: AAT AAA ATC AGC TGG AAA GTG TTG -3’. 
All MRSA isolates underwent SCCmec typing using a multiplex PCR that could detect and 
resolve SCCmec types I through V.34
Statistical Analysis
The Cochran–Armitage trend test was used to compare qacA/B and SCCmec type 
frequencies by year. Statistical significance was tested using the Mantel-Hansel χ2 test, 
univariate logistic regression, Student t test, or Wilcoxon signed rank test as appropriate. A 
2-sided P ≤ .05 was considered significant. Statistical analyses were performed with SPSS 
and SAS v9.3 (SAS Institute, Cary, NC).
This study was approved by the Washington University Human Research Protection Office.
RESULTS
Patient Characteristics
Overall, 1,880 banked MRSA isolates recovered from the anterior nares from 2005 to 2012 
were available for testing. In total, 41 isolates were excluded: 27 were repeat isolates from 
the same patient, 13 were methicillin-susceptible S. aureus on confirmatory testing, and 1 
was from a patient who was not in the SICU at the time of testing (Figure 1). After 
exclusions, MRSA isolates from 504 randomly selected patients (63 per year) were included 
in the study (Figure 1). Characteristics of the study participants are shown in Table 1. 
Notably, 70% of the MRSA isolates were obtained within the first 2 days of SICU 
admission. Among all the MRSA isolates, 36 (7.1%) were qacA/B( + ). There was no 
significant difference in the prevalence of qacA/B MRSA isolates among patients in whom 
MRSA was initially recovered >2 days after ICU admission (10 [27.8%] qacA/B( + ) vs 144 
[30.8%] qacA/B( − ); P = .85). Also, we found no significant difference in the prevalence of 
qacA/B positivity among MRSA isolates relative to transfer from another hospital or facility 
(11 [30.5%] qacA/B( + ) vs 91 [19.5%] qacA/B( − ); P =.13). Compared with patients 
colonized with qacA/B( − ) MRSA isolates, patients colonized with qacA/B( + ) MRSA 
isolates were less likely to have diabetes (5.6% vs 22.3%; P = .02) or congestive heart failure 
(0 vs 13.7%; P = .009) (Table 2).
Prevalence of qacA/B( + ) and mupA( + )
The prevalence of qacA/B( + ) MRSA isolates was 6.2% in the implementation year, then 
this rate fell to 0–1.5% between 2006 and 2008. The prevalence then increased to 16.9% for 
2 years (2009 and 2010) and subsided thereafter, indicating a significant trend for qacA/B (P 
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= .02) (Figure 2). Of the MRSA isolates tested, 35 (6.9%) were mupirocin resistant by the 
diffusion disk method. All of the phenotypically mupirocin-resistant isolates were 
mupA(+ ).
The prevalence qacA/B( + ) isolates obtained <2 days showed a significant trend compared 
with isolates obtained ≥ 2 days of SICU admission (P = .04 for qacA/B <2 days after 
admission vs P =.29 for qac A/B ≥2 days after admission) (Figure 3).
Among all isolates, 9 (1.8%) were both qacA/B( + ) and mupA( + ). These isolates occurred 
in 2005 (n = 1), 2008 (n = 1), 2009 (n = 3), 2010 (n = 3), and 2012 (n = 1). MRSA isolates 
that were qacA/B( + ) were more likely to be mupA(+ ) than qacA/B (−) isolates (25% vs 
5.6%; P = .003) (Table 3).
Characteristics of qacA/B( + ) Isolates Recovered by Year
Due to the observed significant trends, we evaluated the data regarding admission source (ie, 
referred by physician, emergency room (ER), or another facility or acute care facility), 
hospital LOS, LOS prior to SICU admission, and rate of hospital admissions (previous 12 
months) for patients with qacA/B( + ) isolates obtained during 2009–2010 and compared 
them with all other years. We found no significant difference in the admission source (16 
[72.7%] vs 9 [64.3%], P = .72 for admission by physician/ER), hospital stay prior to SICU 
admission (1 [0–6] vs 0 [0–2], P = .23), or total hospital LOS (14.5 [9–23] vs 22 [7–39], P 
= .11). However, compared with qacA/B( + ) isolates from other study years, the qacA/
B( + ) isolates from 2009 and 2010 were more likely to have ≥1 hospital admissions in the 
prior year (20 [90.9%] vs 7 [50.0%]; P = .01) (Table 4).
Prevalence of SCCmec Types
Of the 504 MRSA isolates tested, 10 (2%) were SCCmec type I, 305 (60.5%) were SCCmec 
type II, 3 (0.6%) were SCCmec type III, 184 (36.5%) were SCCmec type IV, and 2 (0.4%) 
were SCCmec type V. The prevalence of MRSA isolates that were SCCmec type IV 
significantly increased from 23.8% in 2005 to 52.4% in 2012 (P < .0001). There was no 
significant difference in the prevalence of qacA/B( + ) by SCCmec type during the study 
period (Table 3).
DISCUSSION
In our 24-bed SICU, the prevalence of qacA/B genes associated with chlorhexidine tolerance 
changed in MRSA nasal isolates over the 8-year study period of daily patient bathing with 
chlorhexidine soap. This change was nonlinear and was associated with an increase in 
prevalence in years 5 and 6 of the study, then decreased in the remaining 2 years. A 
comparison of study patients from 2009 and 2010 versus patients from other study years 
revealed no significant difference in ICU and hospital LOS or rates of hospital admission in 
the prior 12 months. However, patients from these 2 years were more likely to have a MRSA 
isolate cultured from a nasal swab collected within the first 2 days of ICU admission (95 of 
126 [75.4%] vs 247 of 378 [66.9%]; P = .04). Our comparison of qacA/B( + ) isolates from 
2009 and 2010 with qacA/B(+ ) isolates from other study years also revealed no significant 
difference in admission source, hospital LOS and LOS prior to SICU admission; however, 
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qacA/B( + ) isolates from 2009 and 2010 were more likely to have ≥1 hospital admissions in 
the prior year, suggesting a possibility of an expansion of qacA/B ( + ) MRSA at BJH during 
this time period, which resulted in qacA/B( + ) patients in those years being exposed in prior 
admissions. Daily CHG bathing was implemented in 2009 in the other 5 hospital ICUs but 
not on other inpatient units. There was no marked change in the prevalence of MRSA 
isolates containing any of the SCCmec type’s genetic element in these 2 years that would 
suggest a clonal MRSA outbreak in the ICU. We cannot rule out the possibility of 
dissemination of qacA/B due to horizontal transmission of a qacA/B-containing plasmid 
among the endemic MRSA strains in the unit.35 However, the prevalence of this genetic 
element did not remain persistently elevated in the setting of stable daily chlorhexidine use 
throughout the post-implementation period. Our findings suggest that long-term daily 
chlorhexidine bathing at the concentration used in this ICU did not result in sustained, 
widespread dissemination of genes encoding for chlorhexidine tolerance.
The prevalence of high-level phenotypic mupirocin resistance among MRSA nasal isolates 
was 6.9% and remained stable. This finding is similar to that of an earlier study of nasal 
MRSA isolates from patients in this ICU from 2002 to 2004, which reported the high-level 
mupirocin resistance rate to be 8.6%.29 Intranasal mupirocin therapy was not systematically 
used in any area of the hospital during the study period. All high-level mupirocin-resistant 
MRSA isolates we tested contained mupA. Among the MRSA isolates tested, 9 (1.8%) 
contained both chlorhexidine and mupirocin resistance determinants. This prevalence is 
similar to that reported in a study of community-dwelling individuals in St. Louis, Missouri, 
with a history of skin and soft-tissue infections in which 8 of 755 (1.1%) of MRSA isolates 
tested contained both resistance elements.30 Further study is needed to determine whether 
the use of universal decolonization regimens using both chlorhexidine and mupirocin11 leads 
to selection for these dually resistant strains in ICU patients.
The SCCmec type IV mobile genetic element has been associated with community-
associated MRSA strains in the United States and elsewhere,36 whereas isolates with 
SCCmec type II have classically been hospital-associated strains. The proportion of MRSA 
nasal isolates containing the SCCmec type IV mobile genetic element increased steadily 
over the 8-year study period. This finding is consistent with results from other healthcare 
facilities,37,38 suggesting a shift in epidemiology and that community-associated MRSA 
strains are now widely disseminated in healthcare facilities.
The present study has limitations inherent to its retrospective design and the use of patient 
isolates from a single-center site. We were unable to test all the MRSA isolates collected 
during the study period due to limited resources. However, our random sampling 
methodology generated a sample with adequate power (β = 0.8), which was representative of 
the patient population admitted during the study period. All of the isolates evaluated in this 
study were recovered from the anterior nares; thus, we do not know the prevalence of 
qacA/B in MRSA isolates recovered from other body sites. We did not evaluate phenotypic 
tolerance to chlorhexidine; therefore, we may have underestimated less common 
mechanisms of chlorhexidine tolerance.39,40 In addition, we do not know the MIC or 
minimal bactericidal concentration (MBC) of the strains in this study possessing qacA/B. 
Chlorhexidine tolerance among Gram-negative bacteria was not examined in our study. Our 
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study was performed in a single ICU; thus, generalizability of results to other facilities may 
be limited.
Our study has several strengths, including a long follow-up period to evaluate the prevalence 
rate, the use of both phenotypic and genotypic methods to assess mupirocin resistance, a 
standardized surveillance protocol for collection of MRSA nasal isolates, and a well-
established chlorhexidine bathing program in the ICU.
In conclusion, prevalence of qacA/B associated with chlorhexidine tolerance did change 
over time among colonizing MRSA isolates over the 8-year period of daily patient bathing 
with chlorhexidine soap; however, this was not a linear relationship. This change in the 
frequency of qacA/B genes is most likely due to patients in those years being exposed in 
prior admissions. The prevalence of MRSA with SCCmec type IV increased over the study 
period. Further studies are needed to determine whether other ICU-based decolonization 
strategies, such as universal treatment with chlorhexidine and intranasal mupirocin, will 
result in selection of co-resistant isolates.
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FIGURE 1. 
Selection of study population. MRSA, methicillin-resistant S. aureus; MSSA, methicillin-
susceptible S. aureus; SICU, surgical intensive care unit.
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FIGURE 2. 
Prevalence of qacA/B( + ) among sampled MRSA nasal isolates, per year (2005–2012). 
MRSA, methicillin-resistant S. aureus; p, P value.
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FIGURE 3. 
Annual prevalence of qacA/B(+ ) MRSA, stratified by detection <2 days (n= 24) versus ≥2 
days (n = 12) after ICU admission. MRSA, methicillin-resistant S. aureus; p, P value.
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TABLE 1
Patient Characteristics
Patient Characteristic No. (%) (N =504)
Age, y, median (IQR) 63 (48–75)
Female gender 207 (42)
Race
 White 375 (74.4)
 Non-white 129 (25.6)
Medical comorbidities
 CHF 64 (12.7)
 COPD 107 (21.2)
 Diabetes mellitus 106 (21)
 Malignancy 79 (15.7)
 Cirrhosis 19 (3.8)
 Solid organ transplant 6 (1.2)
 ESRD 9 (1.8)
 HIV infection 4 (0.8)
Previous admissions to BJH in prior 12 months
 0 167 (33)
 1–5 201 (40)
 >5 136 (27)
Central venous catheter in place 151 (30)
Days from ICU admission to MRSA (+) culture
 1–2 d 350 (70)
 >2 d 154 (30)
Outcomes
 ICU LOS, d, median (IQR) 3 (2–9)
 Hospital LOS, d, median (IQR) 14 (7–26)
 In-hospital mortality 78 (15.5)
NOTE. IQR, interquartile range; MRSA, methicillin-resistant S. aureus; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; 
ERSD, end-stage renal disease; HIV, human immunodeficiency virus; BJH, Barnes-Jewish Hospital; ICU, intensive care unit; LOS, length of stay.
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TABLE 2
Comparison of Study Participants with MRSA Intranasal Isolates by qacA/B Status
qacA/B(+)
MRSA, No.
(%) (n = 36)
qacA/B(−)
MRSA, No.
(%) (n =468)
P
Value
Age, y, median (IQR) 60 (41–71) 63 (49–75) .24
Female gender 16 (44.4) 191 (40.8) .72
Race
 White 31 (86.1) 344 (73.5) .11
 Non-white 5 (13.9) 124 (26.5)
Medical comorbidities
 CHF 0 64 (13.7) .009
 COPD 6 (16.7) 101 (21.6) .67
 Diabetes mellitus 2 (5.6) 104 (22.2) .02
 Malignancy 3 (8.3) 76 (16.2) .33
 Cirrhosis 0 19 (4.1) .38
 Solid organ transplant 0 6 (1.3) 1.00
 ESRD 1 (2.8) 8 (1.7) .48
 HIV infection 0 4 (0.9) …
Previous admissions to BJH in
 prior 12 moa
 0 11 (30.5) 156 (33.3) .85
 1–5 21 (58.3) 180 (38.5) .11
 > 5 4 (11.1) 132 (28.2) .25
Central venous catheter in
 place
11 (30.6) 140 (30) 1.00
Days from ICU admission to
 MRSA (+) culture
 Days 1–2 26 (72.2) 324 (69.2) .85
 >2 days 10 (27.8) 144 (30.8)
SCCmec type
 Type IV 15 (41.7) 169 (35.9) .47
 Other 21 (58.3) 299 (64.1)
Outcomes
 ICU LOS, d, median (IQR) 5 (2–15) 3 (2–9) .12
 Hospital LOS, d, median
  (IQR)
16 (9–32) 14 (7–26) .74
 In-hospital mortality 2 (5.6) 76 (16.9) .09
Admission referral source
 Physician or ER 25 (69.5) 377 (80.5) .13
 Other acute care hospital or
  other facility
11 (30.5) 91 (19.5)
NOTE. IQR, Interquartile range; MRSA, methicillin-resistant
S. aureus; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ERSD, end-stage renal disease; HIV, human 
immunodeficiency virus; BJH, Barnes-Jewish Hospital; ICU, intensive care unit; LOS, length of stay; ER, emergency room.
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aUnivariate logistic regression (No previous admission as a reference group).
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TABLE 3
Comparison of MRSA Isolate Characteristics by qacA/B Status
qacA/B(+) MRSA,
No. (%) (n = 36)
qacA/B(−) MRSA,
No. (%) (n =468) P Value
mupA(+) 9 (25) 26 (5.6) .003
mupA(−) 27 (75) 442 (94.4)
SCCmec type
I 2 (5.5) 8 (1.7) .15
II 18 (50.0) 287 (61.4) .21
III 0 3 (0.6) .00
IV 15 (41.7) 169 (36.1) .59
V 1 (2.8) 1 (0.2) .13
NOTE. MRSA, methicillin-resistant S. aureus; SCCmec, staphylococcal cassette chromosome mec.
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TABLE 4
Comparison of qacA/B(+) Isolates by Year
qacA/B(+) MRSA
(2009, 2010), No. (%)
(n = 22)
qacA/B(+) MRSA, All Other
Years, No. (%)
(n = 14)
P
Value
Admission referral source
 Physician or ER 16 (72.7) 9 (64.3) .72
 Other acute care hospital or other facility 6 (27.3) 5 (35.7)
Previous admissions
 None 2 (9.1) 7 (50.0) .01
 >1 previous admission 20 (90.9) 7 (50.0)
Length of Stay in days (median, IQR)
 Hospital 14.5 (9–23) 22 (7–39) .31
 SICU 5 (2–12) 5 (2–27) .62
 Prior to SICU admission 1 (0–6) 0 (0–2) .23
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